Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2015

01.09.2015 | short review

ASH 2014 highlights: new therapeutic concepts for T cell lymphomas

verfasst von: MD, PhD A.Prof. Philipp Staber

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Abstract

The Annual Meeting of the American Society of Hematology (ASH) 2014 has highlighted a number of spectacular advances of the past couple of years for T cell lymphomas. These lymphomas are probably the most challenging of all types of hematologic malignancies: First, patients usually present in a very ill condition and in a very advanced stage of disease; second, they do not respond well to chemotherapy; and third, T cell lymphomas are rare diseases. They account for only 15 % of all cases of non-Hodgkin lymphomas and with more than 15 subtypes any subtype is very rare [1]. Therefore, it requires joint forces of an international community to make advances in the understanding of the disease and to identify new treatment approaches. Another reason why the prognosis of T cell lymphomas has been dismal compared with its counterparts in B cell lymphomas is that historically we have applied the therapies from B cell lymphomas to T cell lymphomas. With the advances of large international preclinical studies, we now recognize that the paradigms we learned for B cell lymphomas are inappropriate for T cell lymphomas. An evolving basic science literature suggests that T cell lymphomas are highly enriched for various mutations involving epigenetic operations [2-5]. This might explain why T cell lymphomas are so uniquely poised to be sensitive to the class of epigenetic drugs such as histone deacetylase inhibitors.
Literatur
1.
Zurück zum Zitat Vose J, Armitage J, Weisenburger D; International, T. C. L. P. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–30. doi:10.1200/JCO.2008.16.4558. CrossRefPubMed Vose J, Armitage J, Weisenburger D; International, T. C. L. P. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–30. doi:10.1200/JCO.2008.16.4558. CrossRefPubMed
2.
Zurück zum Zitat Palomero T, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014;46:166–70. doi:10.1038/ng.2873. PubMedCentralCrossRefPubMed Palomero T, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014;46:166–70. doi:10.1038/ng.2873. PubMedCentralCrossRefPubMed
3.
Zurück zum Zitat Sakata-Yanagimoto M, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46:171–5. doi:10.1038/ng.2872. CrossRefPubMed Sakata-Yanagimoto M, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46:171–5. doi:10.1038/ng.2872. CrossRefPubMed
4.
Zurück zum Zitat Yoo HY, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46:371–5. doi:10.1038/ng.2916. CrossRefPubMed Yoo HY, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46:371–5. doi:10.1038/ng.2916. CrossRefPubMed
5.
Zurück zum Zitat Cairns RA, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012;119:1901–3. doi:10.1182/blood-2011-11-391748. PubMedCentralCrossRefPubMed Cairns RA, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012;119:1901–3. doi:10.1182/blood-2011-11-391748. PubMedCentralCrossRefPubMed
6.
Zurück zum Zitat Duvic M, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109:31–9. doi:10.1182/blood-2006-06-025999. PubMedCentralCrossRefPubMed Duvic M, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109:31–9. doi:10.1182/blood-2006-06-025999. PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Coiffier B, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631–6. doi:10.1200/JCO.2011.37.4223. CrossRefPubMed Coiffier B, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631–6. doi:10.1200/JCO.2011.37.4223. CrossRefPubMed
8.
Zurück zum Zitat Lee HZ, et al. FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Clin Cancer Res. 2015. doi:10.1158/1078-0432.CCR-14-3119. Lee HZ, et al. FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Clin Cancer Res. 2015. doi:10.1158/1078-0432.CCR-14-3119.
9.
Zurück zum Zitat Ogura M, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32:1157–63. doi:10.1200/JCO.2013.52.0924. CrossRefPubMed Ogura M, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32:1157–63. doi:10.1200/JCO.2013.52.0924. CrossRefPubMed
10.
Zurück zum Zitat Ansell SM, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372:311–9. doi:10.1056/NEJMoa1411087. PubMedCentralCrossRefPubMed Ansell SM, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372:311–9. doi:10.1056/NEJMoa1411087. PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Piekarz RL, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117:5827–34. doi:10.1182/blood-2010-10-312603. PubMedCentralCrossRefPubMed Piekarz RL, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117:5827–34. doi:10.1182/blood-2010-10-312603. PubMedCentralCrossRefPubMed
12.
Zurück zum Zitat Zelenetz AD, et al. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2003;14 Suppl 1:i5–10. CrossRefPubMed Zelenetz AD, et al. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2003;14 Suppl 1:i5–10. CrossRefPubMed
13.
Zurück zum Zitat Mikesch JH, et al. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center. Ann Hematol. 2013;92:1041–8. doi:10.1007/s00277-013-1738-9. CrossRefPubMed Mikesch JH, et al. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center. Ann Hematol. 2013;92:1041–8. doi:10.1007/s00277-013-1738-9. CrossRefPubMed
14.
Zurück zum Zitat Kretzner L, et al. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Res. 2011;71:3912–20. doi:10.1158/0008-5472.CAN-10-2259. PubMedCentralCrossRefPubMed Kretzner L, et al. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Res. 2011;71:3912–20. doi:10.1158/0008-5472.CAN-10-2259. PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat Zullo KM, et al. Aurora A kinase inhibition selectively synergizes with histone deactylase inhibitor through cytokinesis failure in T-cell lymphoma. Clin Cancer Res. 2015. doi:10.1158/1078-0432.CCR-15-0033. Zullo KM, et al. Aurora A kinase inhibition selectively synergizes with histone deactylase inhibitor through cytokinesis failure in T-cell lymphoma. Clin Cancer Res. 2015. doi:10.1158/1078-0432.CCR-15-0033.
Metadaten
Titel
ASH 2014 highlights: new therapeutic concepts for T cell lymphomas
verfasst von
MD, PhD A.Prof. Philipp Staber
Publikationsdatum
01.09.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-015-0226-4

Weitere Artikel der Ausgabe 3/2015

memo - Magazine of European Medical Oncology 3/2015 Zur Ausgabe